A Phase 1, Open-Label Study that will test BMS-986393 in combination with 3 dual agent combinations of BMS-986393 (a chimeric antigen receptor CAR T-cell) with investigational treatments {Alnuctamab, Mezigdomide or Iberdomide} for safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics.